- Home
- QCRH vs RLAY Comparison
QCRH vs RLAY Comparison
Compare QCRH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QCRH | RLAY |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 2.7B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QCRH | RLAY |
|---|---|---|
| Price | $90.44 | $12.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $98.25 | $19.50 |
| AVG Volume (30 Days) | 85.4K | ★ 3.5M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | 11.62 | ★ 31.78 |
| EPS | ★ 7.49 | N/A |
| Revenue | ★ $165,999,610.00 | $15,355,000.00 |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | $5.59 | $324.03 |
| P/E Ratio | $12.34 | ★ N/A |
| Revenue Growth | 20.72 | ★ 53.44 |
| 52 Week Low | $63.96 | $2.71 |
| 52 Week High | $96.00 | $17.32 |
Technical Indicators
Market Signals| Indicator | QCRH | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 42.94 |
| Support Level | $80.87 | $6.67 |
| Resistance Level | $94.42 | $17.32 |
| Average True Range (ATR) | 2.34 | 1.08 |
| MACD | -0.07 | -0.47 |
| Stochastic Oscillator | 50.87 | 0.32 |
Price Performance
Historical ComparisonAbout QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.